Table 2 Genotype counts and deviation from Hardy–Weinberg equilibrium stratified by disease status and source study

From: Genetic architecture of prostate cancer in the Ashkenazi Jewish population

   

Genotype counts (Hardy–Weinberg P)

SNP

Alleles (Maj/min)

MAF in controls

MSKCC controls

NLGIP controls

Israeli blood bank controls

MSKCC cases

Montreal cases

rs721048

G/A

0.14

7/99/303 (1)

2/46/112 (0.37)

30/299/912 (0.36)

21/214/575 (0.79)

2/11/51 (0.19)

rs2660753

C/T

0.24

27/156/226 (1)

14/50/95 (0.084)

69/445/727 (0.94)

57/297/456 (0.35)

1/21/42 (0.67)

rs9364554

C/T

0.19

10/117/282 (0.72)

10/55/95 (0.66)

51/386/804 (0.59)

32/272/506 (0.59)

5/19/40 (0.28)

rs10486567

G/A

0.29

42/143/224 (0.013)

12/57/91 (0.53)

112/513/614 (0.73)

60/342/408 (0.34)

5/24/34 (0.75)

rs6465657

T/C

0.41

77/188/142 (0.31)

34/82/44 (0.75)

200/578/459 (0.44)

165/386/259 (0.35)

13/27/24 (0.31)

rs7008482

T/G

0.38

68/179/160 (0.14)

22/64/71 (0.22)

175/598/464 (0.47)

104/339/346 (0.16)

5/21/38 (0.49)

rs1016343

C/T

0.19

10/130/269 (0.25)

6/47/107 (0.79)

48/372/819 (0.46)

38/282/489 (0.84)

3/23/38 (1)

rs13254738

A/C

0.41

64/204/141 (0.54)

29/70/61 (0.25)

218/572/447 (0.14)

153/425/232 (0.10)

9/34/21 (0.60)

rs16901979

C/A

0.04

1/34/374 (0.55)

0/10/147 (1)

ND

1/62/748 (1)

0/8/55 (1)

rs6983267

G/T

0.50

96/207/104 (0.77)

36/82/42 (0.87)

318/615/305 (0.82)

168/391/249 (0.52)

12/27/25 (0.43)

rs7000448

C/T

0.48

90/203/116 (1)

39/85/36 (0.53)

279/606/341 (0.77)

234/380/191 (0.14)

16/26/21 (0.21)

rs4242382

G/A

0.065

1/62/345 (0.49)

0/14/146 (1)

4/150/1087 (0.81)

8/125/677 (0.38)

0/5/59 (1)

rs4242384

A/C

0.062

1/57/351 (0.71)

0/12/148 (1)

ND

5/118/687 (1)

0/5/59 (1)

rs7920517

G/A

0.45

81/194/132 (0.55)

42/75/41 (0.53)

250/605/386 (0.65)

150/392/268 (0.77)

12/33/19 (0.80)

rs10993994

T/C

0.50

97/202/109 (0.84)

46/77/35 (0.87)

305/634/301 (0.46)

184/396/229 (0.62)

13/34/17 (0.80)

rs4962416

T/C

0.33

46/193/170 (0.51)

18/78/64 (0.49)

133/516/591 (0.21)

95/344/370 (0.27)

6/25/33 (0.76)

rs7931342

G/T

0.33

46/173/185 (0.57)

20/71/69 (0.86)

149/533/556 (0.23)

69/319/422 (0.44)

6/29/29 (1)

rs10896449

G/A

0.34

52/175/181 (0.38)

20/72/68 (0.86)

155/542/543 (0.28)

76/321/411 (0.27)

6/29/29 (1)

rs4430796

G/A

0.43

69/206/134 (0.54)

35/76/49 (0.63)

225/607/392 (0.73)

183/397/230 (0.67)

11/35/18 (0.46)

rs7501939

C/T

0.44

82/206/121 (0.77)

29/77/52 (1)

222/614/390 (0.49)

131/395/283 (0.77)

13/31/19 (1)

rs1859962

G/T

0.47

99/189/121 (0.14)

27/89/41 (0.11)

ND

157/392/262 (0.67)

14/36/14 (0.45)

rs2735839

G/A

0.18

8/119/281 (0.37)

8/42/110 (0.18)

50/372/818 (0.36)

30/210/570 (0.058)

3/22/39 (1)

rs5945572

G/A

0.25

97/5/307 (NA)

47/2/110 (NA)

303/0/936 (NA)

244/2/563 (NA)

17/0/47 (NA)

  1. Abbreviations: MAF=minor allele frequency; min=minor; maj=major; MSKCC=Memorial Sloan-Kettering Cancer Center; NA=not applicable (X-chromosome SNP and all male study); ND=not done (no data is available on the Illumina chip for these individuals); NLGIP=National Laboratory for the Genetics of Israeli Populations; SNP=single nucleotide polymorphism.
  2. Genotype counts are given as minor homozygote/heterozygote/major homozygote.